

Summary of Studies Supporting USDA Product Licensure

Establishment Name	Intervet Inc.
USDA Vet Biologics Establishment Number	165A
Product Code	1559.2B
True Name	Feline Leukemia-Rhinotracheitis-Calici-Panleukopenia- Chlamydia Psittaci Vaccine, Modified Live & Killed Virus, Modified Live Chlamydia
Tradename(s) / Distributor or Subsidiary (if different from manufacturer)	Merck Animal Health Nobivac Feline 1 HCPCh + FeLV - Merck Animal Health Nobivac Feline 1 HCPCh + FeLV - Merck Sharp & Dohme Saude Animal Ltda. Nobivac Feline 1 HCPCh + FeLV - No distributor specified Nobivac HCPCh+FeLV - Intervet Mexico S.A. de C.V. Nobivac HCPCh+FeLV - No distributor specified Nobivac: Feline 1-HCPCh+FeLV - No distributor specified Procyon HCPCh+FeLV - MSD Salud Animal Columbia S.A.S. Quantum Cat HCP-Chlam + FeLV - No distributor specified
Date of Compilation Summary	April 10, 2019

Disclaimer: Do not use the following studies to compare one product to another. Slight differences in study design and execution can render the comparisons meaningless.

165A 1559.2B Page 1 of 9

Study Type	Efficacy
Pertaining to	Feline Calici Virus (FCV)
Study Purpose	To demonstrate efficacy against FCV.
Product Administration	
Study Animals	Feline
Challenge Description	
Interval observed after	
challenge	
Results	Study data were evaluated by USDA-APHIS prior to product licensure and met regulatory standards for acceptance at the time for submission. No data are published because this study was submitted to USDA-APHIS prior to January 1, 2007, and APHIS only requires publication of data submitted after that date.
USDA Approval Date	August 19, 1999

165A 1559.2B Page 2 of 9

Study Type	Efficacy
Pertaining to	Chlamydia psittaci
Study Purpose	To demonstrate efficacy against <i>C. psittaci</i> .
Product Administration	
Study Animals	Feline
Challenge Description	
Interval observed after	
challenge	
Results	Study data were evaluated by USDA-APHIS prior to product licensure and met regulatory standards for acceptance at the time for submission. No data are published because this study was submitted to USDA-APHIS prior to January 1, 2007, and APHIS only requires publication of data submitted after that date.
USDA Approval Date	August 19, 1999

165A 1559.2B Page 3 of 9

Study Type	Efficacy
Pertaining to	Feline Leukemia Virus (FeLV)
Study Purpose	To demonstrate efficacy against FeLV
Product Administration	
Study Animals	Feline
Challenge Description	
Interval observed after	
challenge	
Results	Study data were evaluated by USDA-APHIS prior to product licensure and met regulatory standards for acceptance at the time of submission. No data are published because this study was submitted to USDA-APHIS prior to January 1, 2007, and APHIS only requires publication of data submitted after that date.
USDA Approval Date	August 19, 1999

165A 1559.2B Page 4 of 9

Study Type	Efficacy			
Pertaining to	Feline Leukemia Vir	us (FeLV)		
Study Purpose	To demonstrate effic	acy against Fe	LV two years afte	r
	vaccination			
Product Administration	Two doses administe	ered by the sub	ocutaneous route 3	weeks apart
Study Animals	23 cats, 52 to 58 days	s of age at tim	e of 1st vaccinatio	n; 12
	vaccinates and 11 co	ntrols		
Challenge Description	Cats were immunosu	ppressed then	challenged with F	eLV two
	years after the 2nd va	accination.		
Interval observed after	Clinical signs were o			
challenge	collected at weekly in	ntervals from	3 to 12 weeks post	-challenge.
Results	<u>Viremia</u> - A positive	animal was de	efined by the prese	ence of
	FeLV during 3 or mo	ore consecutiv	e weeks or a total	of 5 positive
	results during the pos	st-challenge co	ollection period.	
				_
	Group	# of	# Positive for	
	Group	Animals	Viremia	
	Vaccinates	12	2 (17%)	
	Controls	11	11 (100%)	
	Raw data shown on a	attached pages	. Treatment Group	1 is
	vaccinates and Treat	ment Group 2	is controls.	
USDA Approval Date	January 25, 2010	·		

165A 1559.2B Page 5 of 9

FeLV p27 IDEXX ELISA Results (Post-Challenge Phase)

Treatment		6 months prior	Day -2				>	Veeks Po	Weeks Post Challenge	agu			
Group	Animai ib	Day -177	prior to challenge	60	4	5	9	7	8	6	10	11	12
-	JAA1	0.039	0.039	0.050	0.042	0.040	0.042	0.039	0.039	0.044	0.043	0.039	0.035
•	JAB1	0.038	0.037	0.105	0.043	0.053	0.045	0.039	0.039	0.043	0.045	0.040	0.043
-	JAB2	0.040	0.037	0.045	0.043	0.038	0.039	0.040	0.043	0.045	0.045	0.039	0.044
-	JABS	0.039	0.037	0.050	0.042	0.043	0.042	0.039	0.040	0.044	0.045	0.044	0.042
-	JACS	0.040	0.037	0.238	0.409	0.799	0,759	0.944	1.242	1,059	1,404	1.039	1.211
-	JAD3	0.038	0.039	0.040	0.040	0.042	0.042	0.040	0.037	0.042	0.043	0.042	0.043
=	JAES	0.063	0.038	0,040	0.040	0.037	0.042	0.039	0.037	0.040	0.044	0.043	0.043
	JAHB	0.036	0.039	0.040	0.038	0.037	0.040	0.040	0.037	0.040	0.043	0.081	0.043
-	JAI4	0.036	0.038	0.041	0,042	0.039	0.040	0.041	0.038	0.040	0.042	0.043	0.042
-	JAIS	0.037	0.039	0.041	0.039	0.039	0.043	0.041	0.038	0.040	0.044	0.046	0.041
-	JAM2	0.038	0.038	0.126	0.108	0.040	0.043	0.042	0.040	0.044	0.043	0.042	0.043
,-	JAM3	0.037	0.037	0.874	1.078	0.883	0.472	0.752	0.874	1,028	1,692	0.971	0.633
CV	JAA2	0.038	0.039	0.605	0.453	0.805	0.303	0.642	0.552	0,716	1,196	1.027	0,686
Od.	JAB4	0.040	0.036	0.405	0.563	0.955	1.286	1,258	1.258 euthanized	nized			
cv.	JACT	980'0	0.037	1.187	1.061	2.002	1.161	1,844	0.968	1.433	1.706	1.225	1,005
cv.	JAC4	0.040	0.037	0.949	1.036	1.141	0.971	1,561	0.880	1,376	1.531	0.949	1,209
CV.	JAC6	0.038	0.037	1.252	1.222	1,555	0.872	0.793	0.542	0.751	1.128	0.968	0.865
cv	JAC7	0.036	0.037	1.023	0.674	1.417	0.821	1.102	0.947	1.287	1.450	1,007	0.884
CQ.	JAE1	0.037	0.039	0.501	0.405	0.777	0.405	0.758	0.769	0.815	1.343	0.893	0.877
N	JAH	0.037	0.038	0.634	0.653	0.884	0.854	0.873	0.948	0.581	1,440	1.132	1,070
Q	JAK3	0.036	650.0	0.439	0.745	0.850	0.792	0.847	0.868	0,843	1,418	1.036	0.537
Ø	JAME	0.037	0.038	0.441	1.363	1.413	0.794	0.723	1.072	0.732	2.029	1,448	0.549
Q	JANS	0.038	0.039	0.496	0.426	1.045	1.124	1.322	1.125	1.140	1,353	1.178	1.058

Optical diequal to or greater than ouzub are considered positive for helly pz7. Bolded and underlined numbers indicate a positive result.

Study Type	Efficacy
Pertaining to	Feline Rhinotracheitis Virus (FRV)
Study Purpose	To demonstrate efficacy against FRV.
Product Administration	
Study Animals	Feline
Challenge Description	
Interval observed after	
challenge	
Results	Study data were evaluated by USDA-APHIS prior to product licensure and met regulatory standards for acceptance at the time for submission. No data are published because this study was submitted to USDA-APHIS prior to January 1, 2007, and APHIS only requires publication of data submitted after that date.
USDA Approval Date	August 19, 1999

165A 1559.2B Page 7 of 9

Study Type	Efficacy
Pertaining to	Feline Panleukopenia Virus (FPL)
Study Purpose	To demonstrate efficacy against FPL.
Product Administration	
Study Animals	Feline
Challenge Description	
Interval observed after	
challenge	
Results	Study data were evaluated by USDA-APHIS prior to product licensure and met regulatory standards for acceptance at the time for submission. No data are published because this study was submitted to USDA-APHIS prior to January 1, 2007, and APHIS only requires publication of data submitted after that date.
USDA Approval Date	August 19, 1999

165A 1559.2B Page 8 of 9

Study Type	Safety
Pertaining to	ALL
Study Purpose	To demonstrate safety under field conditions.
Product Administration	
Study Animals	Feline
Challenge Description	
Interval observed after	
challenge	
Results	Study data were evaluated by USDA-APHIS prior to product licensure and met regulatory standards for acceptance at the time for submission. No data are published because this study was submitted to USDA-APHIS prior to January 1, 2007, and APHIS only requires publication of data submitted after that date.
USDA Approval Date	April 7, 1992

165A 1559.2B Page 9 of 9